You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2026

AbstractFullPdf
Nov 2021585591210
Dec 2021412412171
Jan 202218118899
Feb 202212613793
Mar 202212413885
Apr 202212513575
May 202214315890
Jun 202220821551
Jul 202212012666
Aug 202211311525
Sep 202216116863
Oct 202214815271
Nov 2022899264
Dec 2022838333
Jan 2023878982
Feb 202310610742
Mar 2023838444
Apr 2023757741
May 2023767833
Jun 2023545526
Jul 2023626330
Aug 2023717134
Sep 202312112243
Oct 202319420048
Nov 202332532631
Dec 202310110244
Jan 2024747546
Feb 2024838321
Mar 2024808265
Apr 2024848552
May 2024838337
Jun 2024747443
Jul 202411011343
Aug 2024595841
Sep 2024555633
Oct 2024657347
Nov 2024949544
Dec 202410210752
Jan 2025818147
Feb 2025858552
Mar 2025888865
Apr 202510410467
May 2025636432
Jun 2025535646
Jul 2025110
Aug 2025110
Oct 2025110
Mar 2026110
Total541455502527